Results 71 to 80 of about 3,573 (200)
The Journal of Headache and Pain, 2020 Background Calcitonin gene-related peptide (CGRP) has recently been implicated in the pathogenesis of post-traumatic headache (PTH), which raises the prospect for therapeutic use of monoclonal antibodies targeting CGRP or its receptor.
Håkan Ashina +14 more
doaj +1 more source
Valu. Erenumab – uus migreeni profülaktiline ravivõimalus [PDF]
, 2018 Eesti Arst 2018; 97(6):333 ...
Braschinsky, Mark
core +1 more source
Mode and site of action of therapies targeting CGRP signaling [PDF]
, 2023 Calcitonin; Headache; MigraineCalcitonina; Dolor de cabeza; MigrañaCalcitonina; Mal de cap; MigranyaTargeting CGRP has proved to be efficacious, tolerable, and safe to treat migraine; however, many patients with migraine do not benefit from drugs that ...
Braniste, Diana +5 more
core +1 more source
Clinical Pharmacology &Therapeutics, Volume 119, Issue 5, Page 1350-1361, May 2026.Regional differences in approved drug dosages and administration are shaped by complex factors, including clinical data, prior regulatory decisions, and region‐specific considerations. This study investigated how such factors are associated with variations in approved doses across the United States Food and Drug Administration (FDA), European Medicines
Sachiko Mita, Shunsuke Ono
wiley +1 more source
Implications of therapy interruption on monthly migraine days and modified migraine disability assessment in patients treated with erenumab for chronic and episodic migraine: SQUARE study interim results. [PDF]
BACKGROUND There are limited real-world data in Switzerland examining the impact of erenumab, a fully human IgG2 monoclonal antibody targeting the calcitonin gene-related peptide (CGRP) receptor, on migraine-related quality of life.
Agosti, Reto +14 more
core +4 more sources
Jefferson Digital Commons quarterly report: April-June 2019 [PDF]
, 2018 This quarterly report includes: Articles CREATE Day Presentations Dissertations From the Archives Grand Rounds and Lectures House Staff Quality Improvement and Patient Safety Posters JCIPE Student Hotspotting Posters Journals and Newsletters MPH ...
Copeland, LIBT, James +1 more
core +2 more sources
European Journal of Neurology, Volume 33, Issue 4, April 2026.Treatment response to anti‐CGRP medications for migraine is typically defined as a ≥ 50% reduction in monthly migraine days. However, the use of patient‐reported outcome measures (such as MIDAS and HIT‐6) has been proposed as alternative options.
Janu Thuraiaiyah +5 more
wiley +1 more source
CPT: Pharmacometrics & Systems Pharmacology, 2023 Erenumab is a fully human anti‐canonical calcitonin gene‐related peptide receptor monoclonal antibody approved for migraine prevention. The Migraine‐Specific Quality‐of‐Life Questionnaire (MSQ) is a 14‐item patient‐reported outcome instrument that ...
Po‐Wei Chen +6 more
doaj +1 more source
The Journal of Headache and Pain, 2022 Background and aims Chronic migraine is a common neurovascular brain disorder with substantial economic costs. We performed a systematic review to identify economic evaluations of pharmacological treatments for adults with chronic migraine.
Saval Khanal +6 more
doaj +1 more source
European Journal of Neurology, Volume 33, Issue 4, April 2026.ABSTRACT Background Although treatment goals in migraine prevention have moved beyond the benchmark of a 50% reduction in monthly attacks, residual disease burden is still evaluated based on residual headache frequency. However, migraine‐related symptoms can persist despite headache freedom, leading to so‐called unclear days that may meaningfully ...
Marcello Silvestro +6 more
wiley +1 more source